GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use

Konstantinos Arvanitakis, Theocharis Koufakis, Djordje Popovic, Giuseppe Maltese, Omar Mustafa, Michael Doumas, Olga Giouleme, Kalliopi Kotsa, Georgios Germanidis

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Purpose of Review
To discuss current literature and provide practical recommendations for the safe and effective use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in people with inflammatory bowel disease (IBD) and type 2 diabetes (T2D) and/or obesity. The molecular mechanisms that justify the potential benefits of GLP-1 RA in IBD and the links between IBD, obesity, and cardiovascular disease are also discussed.

Recent Findings
Preliminary data suggest that GLP-1 RA can modulate crucial pathways in the pathogenesis of IBD, such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity. However, gastrointestinal side effects related to GLP-1 RA need appropriate clinical management to mitigate risks and maximize the benefits of therapy in people with IBD.

Summary
GLP-1 RA originally emerged as drugs for the treatment of hyperglycemia and are currently licensed for the management of T2D and/or overweight/obesity. However, their wealth of pleiotropic actions soon raised expectations that they might confer benefits on non-metabolic disorders. Future studies are expected to clarify whether GLP-1 RA deserve an adjunct place in the arsenal of drugs against IBD.
Original languageEnglish
Pages (from-to)61-74
Number of pages14
JournalCurrent obesity reports
Volume12
Issue number2
Early online date21 Apr 2023
DOIs
Publication statusPublished - Jun 2023

Fingerprint

Dive into the research topics of 'GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use'. Together they form a unique fingerprint.

Cite this